Black Rock Inc. Lian Bio Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.33 - $4.6 $772,102 - $2.67 Million	580,528 Added 94.37%	1,195,716 $5.34 Million
Q3 2023 Nov 13, 2023	SELL	$1.49 - $2.46 $567,920 - $937,641	-381,155 Reduced 38.26%	615,188 $916,000
Q2 2023 Aug 11, 2023	SELL	$1.79 - $2.85 $47,907 - $76,277	-26,764 Reduced 2.62%	996,343 $2.27 Million
Q3 2022 Nov 14, 2022	SELL	$1.87 - $3.0 $16,785 - $26,928	-8,976 Reduced 0.87%	1,023,107 $2.05 Million
Q2 2022 Aug 12, 2022	BUY	$2.15 - $6.01 $1.04 Million - $2.9 Million	482,083 Added 87.65%	1,032,083 $2.23 Million
Q4 2021 Feb 10, 2022	BUY	$6.14 - $16.2 $3.38 Million - $8.91 Million	550,000 New	550,000 $3.39 Million

1.1M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $31.4M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.